Clinical trials: MEK Inhibitor-Associated Retinopathy
MEK Inhibitor-Associated Serous Retinopathy
Investigation of Potential Retinal Toxicity Associated With Hair Dye Products Containing pPD Type Aromatic Amines
Hair dye products could induce minimal forms of MEKAR retinopathies (Mitogen-activated Extracellular signal-regulated Kinase - inhibitors associated retinopathies).
- Trial name
- CAPITOX (NCT04222387)
- Testing
- OCT-B scan
- Where
- France
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Malignant Melanoma, MEK Inhibitor-Associated Retinopathy
Retinal Structural and Functional Changes in Patients Treated With BRAF/MEK Inhibitors
Patients treated with BRAF/MEK inhibitor combinations for malignant melanoma may develop retinal changes known as MEK inhibitor-associated retinopathy (MEKAR).
- Trial name
- NCT07431489
- Testing
- Ophthalmologic Retinal Monitoring During BRAF/MEK Inhibitor Therapy
- Where
- Slovenia
- Volunteers
- 30 people
- Sponsor
- Institute of Oncology Ljubljana
Malignant Melanoma, Drug-Induced Retinopathy
Clinical and Functional Retinal Changes Associated With BRAF/MEK Inhibitor Therapy in Patients With Malignant Melanoma
Patients with malignant melanoma are increasingly treated with combined BRAF and MEK inhibitor therapy. Although this treatment has significantly improved survival outcomes, it has been associated with specific retinal changes…
- Trial name
- NCT07427953
- Where
- Slovenia
- Volunteers
- 14 people
- Sponsor
- Institute of Oncology Ljubljana